Variceal Bleeding: Secondary Prophylaxis
On this page
Direct answer
One drug and one endoscopic procedure together — a non-selective beta-blocker plus band ligation — is what stands between a cirrhotic patient and the next variceal haemorrhage, and the combination outperforms either alone. The beta-blocker is titrated to a heart-rate target (resting rate reduced by about 25%, or to 55–60 per minute), carvedilol is the more potent option where blood pressure tolerates it, and banding continues every 2–4 weeks until varices are eradicated. Rebleeding despite this regimen escalates to a covered TIPS.
What you must remember
- The risk being managed: without secondary prophylaxis, most patients rebleed within one to two years — the justification for starting the regimen immediately after the index bleed is controlled.
- Standard combination: non-selective beta-blocker (propranolol, nadolol, or carvedilol) plus endoscopic variceal ligation — additive reduction in rebleeding versus either alone.
- Propranolol titration: start low (about 20 mg twice daily) and increase until the resting heart rate falls by roughly 25% or reaches 55–60 bpm — the classic exam target; nadolol is the once-daily alternative.
- Carvedilol: 6.25–12.5 mg/day; its added alpha-blocking effect lowers portal pressure more than propranolol at equivalent haemodynamic cost — preferred where tolerated, but watch for hypotension in ascitic patients.
- Contraindications to NSBB: asthma, severe bradyarrhythmia, hypotension; decompensated ascites needs dose caution rather than automatic avoidance.
- EVL schedule: sessions every 2–4 weeks until eradication, then surveillance endoscopy at 3–6 months and 6–12 monthly thereafter — varices regrow, and so does the programme.
- Failure pathway: rebleeding despite combined therapy → covered TIPS (or surgical shunt in well-preserved liver function); transplant evaluation follows.
- Adjuncts from the acute episode: ceftriaxone for 4–7 days reduces infection and rebleeding; over-transfusion (haemoglobin pushed above 7–8 g/dL) refills the portal tree — both are examinable management details.
Building the regimen after the first banding session
A 51-year-old man with alcohol-related cirrhosis survived his first oesophageal variceal bleed — two banding sessions, ceftriaxone for five days, haemoglobin held at 7.5 g/dL. Discharge planning is where secondary prophylaxis is actually written. The endoscopy arm: bands again in 2–4 weeks, repeating until the variceal columns are eradicated, then a check at 3–6 months and 6–12 monthly — the calendar is part of the prescription. The pharmacological arm: carvedilol 3.125 mg twice daily if his blood pressure allows, escalating to 12.5 mg/day while his pulse is watched for the 25% fall or the 55–60 floor — whichever his autonomic system reaches first. Alongside both, the aetiology gets treated, because prophylaxis of the veins without treatment of the liver is half a plan: abstinence counselling and, where relevant, antiviral therapy through the viral hepatitis programme. Then the contingency is rehearsed on the discharge summary itself: any further haematemesis means TIPS, not another round of banding — a covered stent through the hepatic vein into the portal system decompresses the collaterals that banding keeps losing to. The exam rewards the sentence structure: drug plus bands, titrated to the pulse, scheduled to eradication, TIPS on failure — four clauses, no improvisation.
Why the heart rate target matters
The examiner's pharmacology question hides in the pulse: beta-blockers in portal hypertension work by cutting cardiac output and splanchnic vasoconstriction, and the heart rate is the only bedside meter of that dose — hence the 25% reduction or 55–60 bpm target, and hence why " propranolol 20 mg twice daily, fixed forever" is the half-answer that fails the titration mark. The second trap is carvedilol's double edge: more potent portal pressure reduction, but an alpha-mediated drop in systemic pressure that can unseat an ascitic, hypotensive patient — knowing when not to push it is part of knowing the drug. Third, the myths: NSBBs are no longer automatically stopped for SBP or refractory ascites (the pendulum has swung back to individualised judgement), and they are not "contraindicated in all decompensation" — severe hypotension and asthma are the hard stops. Finally, the schedule trap: eradication is not immunity — varices recur after successful banding, which is why the 6–12 monthly surveillance endoscopy exists; candidates who declare the patient "cured after three sessions" miss the lifelong loop the guidelines describe.
Frequently asked questions
What is standard secondary prophylaxis after a variceal bleed?
Combined non-selective beta-blocker and endoscopic variceal ligation — superior to either alone in preventing rebleeding.
How is propranolol titrated?
To a resting heart rate reduced by about 25% or to 55–60 bpm — the clinical proxy for adequate portal pressure reduction.
Why might carvedilol be preferred?
At 6.25–12.5 mg/day it lowers portal pressure more than propranolol (added alpha-blockade), though hypotension limits it in decompensated patients.
What is the EVL follow-up schedule?
Sessions every 2–4 weeks until eradication, then surveillance endoscopy at 3–6 months and 6–12 monthly lifelong, since varices recur.
What is done when rebleeding occurs despite combination therapy?
Covered TIPS (or surgical shunting with good liver reserve), with transplant evaluation — escalation is planned, not improvised.